Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2 Tumor-Agnostic 1 NET 1 Endocrine 1

Conditions

Neuroendocrine Tumors 1

Interventions

Magnetic Resonance Spectroscopy 15 lutetium Lu 177 dotatate 14 Specimen Handling 14 cabozantinib 10 Nivolumab 10 Everolimus 8 pembrolizumab 7 gallium Ga 68 dotatate 6 Ipilimumab 6 Cisplatin 5 Carboplatin 5 trametinib 4 olaparib 4 lenvatinib 4 X-Rays 4 Lutetium-177 4 Etoposide 4 Cyclophosphamide 4 CTLA-4 Antigen 4 fluorodopa F 18 3 fludarabine 3 dabrafenib 3 cemiplimab 3 Temozolomide 3 Phantoms, Imaging 3 Fluorodeoxyglucose F18 3 Blood Specimen Collection 3 177Lu-octreotide, DOTA(0)-Tyr(3)- 3 selpercatinib 2 lanreotide 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Yttrium-90 × Endocrine × 90 days × Clear all

NCT04339036 2026-06-04

CapTemY90

Abramson Cancer Center at Penn Medicine

Phase 2 Recruiting

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡